Skip to main content

Table 2 Distribution of Kidney Lesion Subtype for A/J and C57BL/6 Tsc2+/- Cohorts

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

 

% of Total Score per Kidney

Tsc2+/-Cohort (strain, treatment, age)

Cyst

Pre-papillary

Papillary

Solid

C57BL/6, untreated, 9 months

13.34

26.67

45.88

14.11

C57BL/6, untreated, 12 months

8.64

34.15

43.21

8.64

A/J, untreated, 3 months

11.54

19.23

57.69

11.54

A/J, untreated, 5 months

9.47

21.59

62.12

6.82

A/J, untreated, 7 months

4.98

23.6

60.17

11.26

A/J, untreated, 9 months

12.38

21.27

53.63

12.51

A/J, untreated, 12 months

11.18

16.75

59.07

13.52

Group 1

A/J rapa daily × 4 weeks then weekly × 8 weeks

31.4

51.44

14.83

0.87

Group 2

A/J rapa daily × 4 weeks

18.08

58.67

22.64

0.91

Group 3

A/J rapa weekly × 12 weeks

20.88

65.86

13.02

0.25